REMARKS

This amendment is submitted in response to the Examiner's telephonic restriction requirement. There is no new matter added, and entry of the amendment is respectfully requested.

Claims 1-93 have been cancelled. New claims 94-100 are added. New claims 94-100 are supported by original claims 18, 20 and 64. No new matter is added an entry of the amendment is respectfully requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: June 8, 2004

Jason I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212) 840-0097